On October 15, 2026, AstraZeneca is trading at £12,300.00, up 3.40%, after a healthcare-sector rally following UnitedHealth’s stronger-than-expected third-quarter earnings and raised 2026 profit outlook supported sector sentiment.
- Reports cite a Nordea upgrade and positive pipeline developments that may also have supported interest.
- AstraZeneca’s $2 billion Summit Therapeutics investment was announced earlier in October; available evidence does not establish these company-specific items as the direct cause of this session’s move.